0
Obstructive Lung Diseases |

Effect of Statin Therapy in Patients With Chronic Obstructive Airway Disease

Hamdy Mohammadien, MD; Mahmoud Hamdy Abdel Rahim, MD; Fatten omenra, MD; Eman ahmed, MD
Author and Funding Information

Sohag University-Sohag Faculty of Medicine, Sohag-Elmaragha-Nagecc Elhakim, Egypt


Chest. 2015;148(4_MeetingAbstracts):745A. doi:10.1378/chest.2215665
Text Size: A A A
Published online

Abstract

SESSION TITLE: Emerging Therapies in COPD

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 27, 2015 at 02:45 PM - 04:15 PM

PURPOSE: To evaluate the effect of daily used statins on inflammatory markers (CRP, IL6, neutrophil count), antioxidant enzymes (Superoxide dismutase, Catalase), Nitric oxide,pulmonary function tests ,arterial blood gases,frequency of hospitalization for AECOPD and number of intensive care unit ICU admissions in COPD patients.

METHODS: One hundred COPD patients were included. The patients were allocated into two groups: 1-Group 1: Fifty COPD patients who had statins in their treatment, atorvastatin, in a dose of 20mg once daily orally for one year. 2-Group 2: Fifty COPD patients who are not receiving statins as control group. PFTs, ABG, CRP, IL6, Superoxide dismutase (SOD), Catalase, Nitric oxide, Lipid profile, CBC& liver & kidney function tests were performed in all patients before, 6 months & one year after initiation of therapy.

RESULTS: 100 COPD patients (84% male) with mean age 62.1±1 (ranged 40-90 years) were included. Pulmonary function & PaO2 significantly increased & PaCO2 decreased in statin users compared with non statin users (0.001, 0.004 & 0,02). CRP was significantly higher in statin users compared to non statin users (0.001) at baseline, but after statin therapy there is highly significant decrease in serum CRP & IL6. Plasma levels of catalase, SOD & NO were significantly higher in statin non users than statin users (0.001) (at baseline) but after 12 ms of statin therapy there is highly significant increase in plasma levels of SOD, catalase & NO (0.001). There is highly significant decrease in neutrophil count after 6 & 12 ms of statin therapy (0.002 & 0.001).Also after 12 msof therapy there is significant decrease in ICU admission (0.03) and highly significant decrease in hospital admission (0.001). No mortality in statin users but 4% mortality in non users.

CONCLUSIONS: Treatment with statins may reduced lung function decline, hospital & ICU admission,also ↓ed inflammatory markers &↑ed NO, antioxidant enzymes in COPD patients.

CLINICAL IMPLICATIONS: Statins may be used adjavent therapy in COPD patients as a result of its antiinflammatory effect.

DISCLOSURE: The following authors have nothing to disclose: Hamdy Mohammadien, Mahmoud Hamdy Abdel Rahim, Fatten omenra, Eman ahmed

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543